Denali Therapeutics to Highlight Progress Across Broad Biotherapeutics Portfolio for Neurodegeneration Enabled by Its Blood-Brain Barrier (BBB) TV Platform at Virtual R&D Day Today
October 15, 2020 08:00 ET | Denali Therapeutics Inc.
Proprietary and differentiated Transport Vehicle (TV) technology shows potential to solve the BBB challenge by delivering biotherapeutics to the brainNew preclinical data support the potential for...
arvinas logo.jpg
Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins
October 14, 2020 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Neosensory Logo.png
Neosensory Strengthens Leadership Through Appointment of Dr. Kevin Liebe, AuD, as Scientific Advisor
October 06, 2020 11:00 ET | Neosensory
PALO ALTO, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Neosensory, a neuroscience-based company that empowers people with new senses, today announced that Dr. Kevin Liebe, AuD, has joined the company...
Why Did I Eat That? Obesity and the Neuroscience of Food Craving - A Free Webinar from the Brain & Behavior Research Foundation
October 05, 2020 09:00 ET | Brain & Behavior Research Foundation
New York, Oct. 05, 2020 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation is hosting a free webinar “Why Did I Eat That? Obesity and the Neuroscience of Food Craving” on Tuesday,...
ISG Smartalks™ Webinar to Look at How Neuroscience and Technology Can Boost Cybersecurity
September 16, 2020 10:00 ET | Information Services Group, Inc.
STAMFORD, Conn., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Enterprises can boost their cybersecurity by adopting neuroscience principles to drive awareness and cultural change among employees and business...
NOVARTIS logo.jpg
Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)
September 11, 2020 11:05 ET | Novartis International AG
Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1 Subgroup analyses of the EXPAND trial showed the value of...
NOVARTIS logo.jpg
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
September 11, 2020 11:00 ET | Novartis International AG
New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates and MRI lesion activity and demonstrated...
NOVARTIS logo.jpg
Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum
September 08, 2020 01:15 ET | Novartis International AG
Novartis will present 48 abstracts from its leading MS portfolio, including new data on recently FDA-approved Kesimpta® (ofatumumab)—the first and only self-administered, targeted B-cell therapy for...
NOVARTIS logo.jpg
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
August 20, 2020 13:30 ET | Novartis International AG
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple...
NOVARTIS logo.jpg
Novartis announces US District Court for the District of Delaware upholds validity of Gilenya® (fingolimod) dosage regimen patent
August 17, 2020 13:11 ET | Novartis International AG
Basel, August 17, 2020 — Novartis welcomes the decision by the US District Court for the District of Delaware to uphold the validity of the Gilenya® (fingolimod) dosage regimen patent, as our...